ArticleBMC microbiology2026
RSM-optimized co-encapsulation of Lactobacillus brevis LSe and FOS in calcium alginate: enhancing encapsulation efficiency and bacterial growth.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis study optimized the co-encapsulation of the probiotic Lactobacillus brevis strain LSe and the prebiotic fructo-oligosaccharide (FOS) in calcium alginate beads using a Central Composite Design (CCD).
resultsThe statistically derived optimal formulation (3.0% w/v sodium alginate, 1.2% w/v FOS, and 2.0% w/v CaCl₂) achieved high initial and 24-h encapsulation efficiencies of 84.7 ± 2.8% and 99.2 ± 1.2%, respectively. Encapsulated cells showed markedly improved growth in culture medium compared to free cells (OD₆₀₀ = 0.70 vs. 0.15). Under simulated GI conditions, encapsulation maintained high viability at pH 2.0, but survival rates did not significantly differ between encapsulated and free cells in simulated gastric juice, intestinal juice, or bile salt solutions (0.3-1.2% w/v).
conclusionsFor this specific strain and formulation, the primary benefits of encapsulation are enhanced initial loading and growth promotion rather than substantial GI protection. Nonetheless, the high encapsulation efficiency and improved growth kinetics support the FOS/alginate system as a promising delivery vehicle for L. brevis LSe in functional foods. This study establishes the first RSM-optimized protocol for this co-encapsulation, providing a reproducible framework for future synbiotic delivery system development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.